Resalis Therapeutics is a biotechnology company developing non-coding RNA drug candidates for metabolic diseases. The company is focusing on its lead program, RES-010, which aims to provide disease-modifying therapeutic impact including weight loss and reduction of hepatic steatosis.

Resalis Therapeutics

Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. 
 
The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis.

Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.

Italian Angels for Growth

Claris Ventures

Club degli Investitori

Finpiemonte

Today we want to celebrate the fact that our CSO, Riccardo Panella, has published three impactful papers in 2023, shedding light on the critical role of microRNA-22 and the benefits of inhibiting it with our antisense oligonucleotide, RES-010. These publications underline the promising therapeutic benefits of RES-010 in treating metabolic disorders and potentially even cancer. We are excited about the future and the impact this research will have on patients’ lives.

These are his publications:

1.    MicroRNA-22 is a Key Regulator of Lipid and Metabolic Homeostasis, International Journal of Molecular Science
2.    Assessment of Immunostimulatory Responses to the antimiR-22 Oligonucleotide Compound RES-010 in Human Peripheral Blood Mononuclear Cells, Frontiers in Pharmacology.
3.    Targeting of MicroRNA-22 Suppresses Tumor Spread in a Mouse Model of Triple-Negative Breast Cancer, Biomedicines

Exciting Opportunity: Join Our Team as a Publications Lead! 🌟
We are thrilled to announce an opening for a dynamic and experienced Publications Lead to join Resalis Therapeutics on a part-time or consultant basis! If you are 🚀 passionate about scientific communication and have a proven track record in managing publications within the biotech or pharmaceutical industry, we want to hear from you! 💥

Resalis Therapeutics is tackling metabolic disorders with the power of non-coding RNAs!  Their research on RES-010 shows promise for obesity treatment. Top startup for a reason! Learn more: https://lnkd.in/ess48Zc #ItalianStartups #HealthTech #BioTech

At Resalis, we aim to harness the body’s physiology to effectively combat obesity and achieve lasting results. Our new mode of action video explains how our lead program, RES-010, targets the underlying mechanism.

Metabolic diseases are regulated through multiple cellular pathways. Instead of finding a high-precision downstream target, we have identified an important upstream player who is orchestrating multiple pro-lipogenic programs. Our product candidate RES-010 specifically targets this central player, miR-22, enabling the transformation of white adipose tissue into brown adipose tissue. It increases fatty acid oxidation and energy expenditure and reduces lipid biosynthesis. Therefore, it specifically increases cellular metabolism and decreases only fat mass.

Once considered a problem only in high-income countries, overweight and obesity are on the rise worldwide. In 2022, over 390 million children and adolescents aged 5-19 were overweight, highlighting a growing global health crisis.

Childhood obesity not only increases the risk of serious comorbidities such as diabetes and cardiovascular diseases but also has severe psychosocial consequences. It negatively impacts school performance and quality of life, often compounded by stigma, discrimination, and bullying. Furthermore, many affected children face a double burden of malnutrition, dealing with both undernutrition and obesity, exacerbating health risks.

At Resalis, we are developing therapeutic options that do not foster weight loss by reducing appetite but aim to promote metabolic changes, specifically converting white adipose tissue to brown adipose tissue, thereby increasing energy usage and enabling a lasting weight loss effect.

COM:RESALISTHERAPEUTICS

Resalis Therapeutics

locale

market

industry

website

linkedin

founding date

peer of

investor of

Metrics